Potent fluoromethyl ketone inhibitors of recombinant human calpain I

Bioorganic and Medicinal Chemistry Letters

Volumn 6, Issue 11, 1996, Pages 1237-1240

  Chatterjee, Sankar ^a   Josef, Kurt ^a   Wells, Gregory ^a   Iqbal, Mohamed ^a   Bihovsky, Ron ^a   Mallamo, John P ^a   Ator, Mark A ^a   Bozyczko Coyne, Donna ^a   Mallya, Satish ^a   Senadhi, Shobha ^a   Siman, Robert ^a  

^a CEPHALON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALPAIN; CALPASTATIN; CATHEPSIN B; CATHEPSIN L; TETRAHYDROISOQUINOLINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; DRUG POTENCY; DRUG SYNTHESIS; KETOGENESIS; MOTOR NEURON DISEASE; MUSCLE ATROPHY; MUSCULAR DYSTROPHY; STROKE;

EID: 0029950794     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0960-894X(96)00209-0     Document Type: Article

References (24)

1. Croall, D. L.; DeMartino, G. N. Physiol. Rev. 1991, 71, 813.
2. Wang, K. K. W.; Yuen, P. Trends Pharm. Sci. 1994, 15, 412.
3. (a) Mehdi, S. Trends Biol. Sci. 1991, 16, 150;
4. (b) Harbeson, S. L., Abelleira, S. M.; Akiyama, A.; Barrett, R., III,; Carroll, R. M.; Straub, J. A.; Tkacz, J. N.; Wu, C.; Musso, G. F. J. Med. Chem 1994, 37, 2918;
5. (c) Li, Z.; Patil, G.; Golubski, Z. E.; Hori, H.; Tehrani, K.; Foreman, J. E.; Eveleth, D. D.; Bartus, R. T.; Powers, J. C. J. Med. Chem. 1993, 36, 3472.
6. (a) Crawford, C.; Mason, R. W.; Wickstrom, P.; Shaw, E. Biochem. J. 1988, 253, 751;
7. (b) McGowan, E. B.; Becker, E.; Detwiler, T. C. Biochem. Biophys. Res. Commun. 1989, 158, 432;
8. (c) Huang, Z.; McGowan, E. B.; Detwiler, T. C. J. Med. Chem 1992, 35, 2048;
9. (d) Harris, A. L.; Gregory, J. S., Maycock, A. L.; Graybill, T. L.; Osifo, I. K.; Schmidt, S. L.; Dolle, R. E. Bioorg. Med. Chem. Lett. 1995, 5, 393.
10. (a) Angliker, H.; Anagli, J.; Shaw, E. J. Med. Chem. 1992, 35, 216.
11. (b) Peptidyl fluoromethyl ketones were first reported in the literature by Rasnick; see, Rasnick, D. Anal. Biochem. 1985, 149, 461.
12. Imperiali, B.; Abeles, R. H. A Tetrahedron Lett. 1986, 27, 135.
13. Revesz, L.; Briswalter, C.; Heng, R.; Leutwiler, A.; Mueller, R.; Wuethrich, H. J. Tetrahedron Lett. 1994, 35, 9693.
14. Wegler, R.; Bodenbenner, K. Ann. Chem 1959, 624, 25.
15. Majer, P.; Randad, R. S. J. Org. Chem. 1994, 59, 1937.
16. Meyer, S. L.; Bozyczko-Coyne, D.; Mallya, S. K.; Spais, C. M.; Bihovsky, R.; Kawooya, J. K.; Lang, D. M.; Scott, R. W; Siman, R. Biochem. J. 1996, 314, 511.
17. Tian, W ; Tsou, C. Biochemistry 1982, 21, 1028.
18. m), correcting for the effect of substrate on the inactivation rate.
19. Krantz, A.; Copp, L. J.; Coles, P. J.; Smith, R. A.; Heard, S. B. Biochemistry 1991, 30, 4678.
20. 13 using Cbz-Phe-Arg-AMC as substrate.
21. Rates of inactivation of cathepsin L were determined under the assay condition described by Mason et al. using Cbz-Phe-Arg-AMC as substrate; see, Mason, R.W.; Green, G. D. J., Barrett, A. J. Biochem. J. 1985, 226, 233.
22. Pliura, D. H.; Bonaventura, B. J.; Smith, R. A.; Coles, P. J.; Krantz, A. Biochem. J. 1992, 288, 759.
23. Parkes, C.; Kembhavi, A. A.; Barrett, A. J. Biochem. J. 1985, 230, 509.
24. 1 pocket, leading to a destabilizing interaction." We thank her/him for bringing this alternate explanation to our attention.